PCS-2023 > 3 > 3E > 3E0 > 3E0M |
3E0 | Physiological Systems and Anatomical Regions, Introduction | |
Info: | Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products | |
3E0M | Introduction, Peritoneal Cavity | |
3E0M0 | Open | |
3E0M05 | Adhesion Barrier | |
3E0M05Z | Introduction of Adhesion Barrier into Peritoneal Cavity, Open Approach | |
3E0M3 | Percutaneous | |
3E0M30 | Antineoplastic | |
3E0M304 | Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Percutaneous Approach | |
3E0M305 | Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach | |
3E0M30M | Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach | |
3E0M30Y | Introduction of Hyperthermic Antineoplastic into Peritoneal Cavity, Percutaneous Approach | |
3E0M32 | Anti-infective | |
3E0M328 | Introduction of Oxazolidinones into Peritoneal Cavity, Percutaneous Approach | |
3E0M329 | Introduction of Other Anti-infective into Peritoneal Cavity, Percutaneous Approach | |
3E0M33 | Anti-inflammatory | |
3E0M33Z | Introduction of Anti-inflammatory into Peritoneal Cavity, Percutaneous Approach | |
3E0M35 | Adhesion Barrier | |
3E0M35Z | Introduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Approach | |
3E0M36 | Nutritional Substance | |
3E0M36Z | Introduction of Nutritional Substance into Peritoneal Cavity, Percutaneous Approach | |
3E0M37 | Electrolytic and Water Balance Substance | |
3E0M37Z | Introduction of Electrolytic and Water Balance Substance into Peritoneal Cavity, Percutaneous Approach | |
3E0M3B | Anesthetic Agent | |
3E0M3BZ | Introduction of Anesthetic Agent into Peritoneal Cavity, Percutaneous Approach | |
3E0M3H | Radioactive Substance | |
3E0M3HZ | Introduction of Radioactive Substance into Peritoneal Cavity, Percutaneous Approach | |
3E0M3K | Other Diagnostic Substance | |
3E0M3KZ | Introduction of Other Diagnostic Substance into Peritoneal Cavity, Percutaneous Approach | |
3E0M3N | Analgesics, Hypnotics, Sedatives | |
3E0M3NZ | Introduction of Analgesics, Hypnotics, Sedatives into Peritoneal Cavity, Percutaneous Approach | |
3E0M3T | Destructive Agent | |
3E0M3TZ | Introduction of Destructive Agent into Peritoneal Cavity, Percutaneous Approach | |
3E0M3G | Other Therapeutic Substance | |
3E0M3GC | Introduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Approach | |
3E0M3S | Gas | |
3E0M3SF | Introduction of Other Gas into Peritoneal Cavity, Percutaneous Approach | |
3E0M4 | Percutaneous Endoscopic | |
3E0M45 | Adhesion Barrier | |
3E0M45Z | Introduction of Adhesion Barrier into Peritoneal Cavity, Percutaneous Endoscopic Approach | |
3E0M4G | Other Therapeutic Substance | |
3E0M4GC | Introduction of Other Therapeutic Substance into Peritoneal Cavity, Percutaneous Endoscopic Approach | |
3E0M7 | Via Natural or Artificial Opening | |
3E0M70 | Antineoplastic | |
3E0M704 | Introduction of Liquid Brachytherapy Radioisotope into Peritoneal Cavity, Via Natural or Artificial Opening | |
3E0M705 | Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening | |
3E0M70M | Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening | |
3E0M7S | Gas | |
3E0M7SF | Introduction of Other Gas into Peritoneal Cavity, Via Natural or Artificial Opening |
ICD-10-CM-2023 Code Search Engine and PCS-2023 Code Search Engine |